Oncology Convergence Inc.

Oncology Convergence Inc. U.S. based oncology billing, oncology coding, prior auth, insurance benefits verification, A/R and revenue cycle management experts.

Helping hospital based and freestanding oncology practices thrive by capturing every penny of charges they're owed.

Cancer treatments account for 41% of all 340B drug purchases. Keytruda alone generated $6.9 billion in 340B sales in 202...
01/21/2026

Cancer treatments account for 41% of all 340B drug purchases. Keytruda alone generated $6.9 billion in 340B sales in 2023.

The financial impact is extraordinary:

• 340B margin for cancer therapies = 45% of total reimbursement
• Non-340B providers earn just 4% margin on the same drugs
• "Penny pricing" can create margins approaching 100% on established chemotherapies

But this opportunity comes with extreme complexity:

• Weight-based dosing requiring precise unit conversions
• Combination therapy protocols with multiple billing codes
• Novel immunotherapies with evolving coverage policies
• State-specific modifier requirements varying by Medicaid program

The convergence of high financial value and operational complexity makes specialized oncology billing expertise not just valuable—but essential.

Your hospital wrote it off as worthless.We see $600K in recoverable revenue. 💰Most hospitals write off oncology claims a...
01/20/2026

Your hospital wrote it off as worthless.

We see $600K in recoverable revenue. 💰

Most hospitals write off oncology claims at 270 days.

But here's what they don't know: 30-35% of those "uncollectible" claims are actually recoverable with the right expertise.

For a hospital with 5 medical oncologists, that's $600K-$700K in pure profit sitting in old files.
✅ No upfront cost
✅ No risk to you
✅ We only get paid when you do

Infusion Revenue Recovery (IRR) turns your write-offs into cash.

Stop leaving money on the table. 👉 oncologyconvergence.com/contact-us

Let me share a statistic that should get every DSH hospital CFO's attention:Each oncologist in your program could be gen...
12/01/2025

Let me share a statistic that should get every DSH hospital CFO's attention:

Each oncologist in your program could be generating over $1 million in 340B margin. 🏥

Sound too good to be true? It's actually a commonly cited benchmark in the industry, and here's why the math works:

Oncology is the powerhouse of 340B programs, accounting for 41% of all 340B drug purchases nationwide. With margins that can hit 45% of total reimbursement, the financial impact is massive.

But here's what keeps me up at night (and probably you too): How many hospitals are actually capturing that full potential?

340B oncology billing is notoriously complex. Compliance requirements are strict. Documentation must be airtight. One small process gap, and you're watching significant margin slip away—margin that funds uncompensated care, supports essential services, and enables your mission.

The good news? With the right expertise and systems, optimizing your 340B oncology revenue cycle is absolutely achievable.

At Oncology Convergence, this is literally all we do. We've helped countless hospital-based oncology practices identify profit leaks, implement compliant processes, and maximize their 340B capture. Our team has deep oncology expertise (15+ years on average) and proprietary software that finds the revenue you're missing.

Is your 340B program performing at its peak? Let's find out together: https://bit.ly/3Msnn3D

Walking the 340B tightrope? One misstep can cost millions. 🎪DSH hospitals save a median of $8.9 million annually through...
11/27/2025

Walking the 340B tightrope? One misstep can cost millions. 🎪

DSH hospitals save a median of $8.9 million annually through 340B—but the program's complexity creates serious exposure:

• Manufacturer repayments
• Financial penalties
• Program expulsion

With oncology representing 41% of 340B purchases and margins reaching 45% of reimbursement, your oncology revenue cycle is both your greatest opportunity and your highest-risk area.

You need more than compliance—you need optimization. Oncology Convergence brings specialized expertise to navigate 340B complexities while maximizing your financial performance.

🎯 Balance risk and reward with confidence: https://bit.ly/3BKDOpL

Understanding the True Value of Hospital-Based Oncology Programs: A 340B PerspectiveIf you're leading financial or opera...
11/25/2025

Understanding the True Value of Hospital-Based Oncology Programs: A 340B Perspective

If you're leading financial or operational strategy at a DSH hospital, understanding your oncology program's 340B contribution is critical.

The Financial Reality: Research indicates that oncologists at DSH hospitals commonly generate over $1 million in 340B margin annually. This isn't an outlier—it reflects oncology's role as the dominant category in 340B utilization, representing 41% of all program drug purchases. With reimbursement margins that can reach 45%, the financial impact is substantial.

Why This Matters: 340B margin isn't discretionary profit—it's mission-critical funding that supports:

• Uncompensated care delivery
• Financially challenged service lines
• Community health programs
• Your hospital's safety-net role

The Challenge: Capturing this margin requires navigating one of healthcare's most complex revenue cycles. 340B compliance requirements are stringent. Oncology billing involves intricate coding, prior authorization management, and reimbursement optimization. Process gaps at any point can result in significant revenue leakage.

The Solution: Specialized expertise in oncology revenue cycle management isn't a luxury—it's essential to program performance. At Oncology Convergence, we bring deep oncology-specific knowledge (our team averages 15+ years of experience), proprietary auditing technology, and proven implementation strategies to help hospital-based programs maximize compliant 340B capture.

We don't just identify problems—we implement sustainable solutions that protect your margin and your mission.

Ready to optimize your oncology 340B program? Start with a comprehensive revenue cycle audit: https://bit.ly/3Msnn3D

Is each of your oncologists generating over $1 million in 340B margin for your hospital? 🏥For DSH hospitals, this isn't ...
11/24/2025

Is each of your oncologists generating over $1 million in 340B margin for your hospital? 🏥

For DSH hospitals, this isn't aspirational—it's an industry benchmark. Oncology services drive 41% of all 340B drug purchases, with margins reaching up to 45% of total reimbursement.

This revenue funds uncompensated care, supports struggling service lines, and enables your community mission. But only if your revenue cycle is optimized to capture it compliantly.

At Oncology Convergence, we specialize in maximizing 340B oncology value while maintaining strict compliance. Don't leave critical funding on the table.

👉 Let's optimize your 340B revenue cycle: https://bit.ly/3BKDOpL

340B compliance failures often originate from data disconnects between pharmacy, clinical, and billing systems.The chain...
11/22/2025

340B compliance failures often originate from data disconnects between pharmacy, clinical, and billing systems.

The chain of risk is clear:

• Pharmacy purchasing error
• Clinical documentation gap
• Split-billing software misconfiguration
• Billing modifier mistake
• HRSA audit finding
• Manufacturer repayment demand

Consider the complexity:

• Every dose administered must be tracked from 340B purchase through patient eligibility verification to correct billing modifier application.
• NDC mappings must be precise.
• Virtual inventory systems require perfect data feeds from EMRs.

A single oncologist treating 200 patients monthly generates thousands of data points that must align perfectly across multiple systems. This level of operational precision demands specialized expertise in both 340B regulations and oncology workflows.

Maximize Your Mission Funding$1 million per oncologist. 41% of all 340B purchases. Up to 45% margins. 🏥These aren't vani...
11/22/2025

Maximize Your Mission Funding

$1 million per oncologist. 41% of all 340B purchases. Up to 45% margins. 🏥

These aren't vanity metrics—they're the financial foundation of your community mission. For DSH hospitals, 340B oncology revenue funds the care that wouldn't otherwise be possible.

But capturing this value requires more than participation. It demands specialized revenue cycle expertise that ensures compliant, optimized billing processes across your oncology service line.

Oncology Convergence exists for this exact purpose: helping DSH hospitals maximize 340B performance while maintaining bulletproof compliance.

💼 Let's strengthen your financial lifeline together: https://bit.ly/3BKDOpL

The $1 Million Question for DSH Hospital Leaders:Are you capturing the full 340B margin potential in your oncology progr...
11/21/2025

The $1 Million Question for DSH Hospital Leaders:

Are you capturing the full 340B margin potential in your oncology program?

Here's what's at stake: Oncology represents 41% of all 340B drug purchases, with margins reaching up to 45% of total reimbursement. For many DSH hospitals, that translates to over $1 million in margin per oncologist annually.

But here's the challenge—340B oncology revenue cycles are incredibly complex. Between compliance requirements, billing intricacies, and reimbursement optimization, even small gaps in your process can cost you hundreds of thousands of dollars.

The impact goes beyond your bottom line: This margin funds the uncompensated care your community depends on. It keeps essential service lines operational. It allows you to live out your mission every single day.

That's why optimizing your 340B oncology revenue cycle isn't just good business—it's essential to serving your patients.

Oncology Convergence specializes in helping hospital-based oncology practices maximize compliant 340B revenue capture. Our proprietary auditing software identifies exactly where you're losing money, and our experienced team implements solutions that last.

Don't leave this critical funding on the table. Contact us today: https://bit.ly/3Msnn3D

DSH eligibility hinges on maintaining a Medicare DSH adjustment percentage above 11.75%. This calculation uses prior-yea...
11/21/2025

DSH eligibility hinges on maintaining a Medicare DSH adjustment percentage above 11.75%. This calculation uses prior-year data, creating perpetual uncertainty.

The COVID-19 pandemic starkly illustrated this vulnerability. Public health measures caused many hospitals' Medicaid patient volumes to drop, threatening their DSH status through no fault of their own. Congress had to enact emergency legislation to preserve eligibility.

Meanwhile, hospitals must navigate:

• GPO prohibition requirements for outpatient drugs
• Complex inventory management across multiple purchasing accounts
• Continuous recertification with HRSA
• Contract pharmacy oversight and audit requirements

When your 340B eligibility is precarious and the financial stakes are measured in millions, revenue cycle precision becomes a survival imperative.

Address

9200 E Mineral Avenue #100
Centennial, CO
80122

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+16024419520

Website

http://OCInfusion.com/

Alerts

Be the first to know and let us send you an email when Oncology Convergence Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Oncology Convergence Inc.:

Shortcuts

Share

Category